ENTITY
SMARTSCORE: 2.4/5

4SC (VSC GR)

8
Analysis
Health CareGermany
4SC AG operates as a biotechnology company. The Company focuses on the development of novel small molecule drugs for cancer treatment. 4SC serves the healthcare sector in Germany.
more
bullish4SC
17 Aug 2018 14:23Issuer-paid

4SC - Domatinostat R&D ramp-up in H218

During the Q218 results call, 4SC management announced that with current funds, it plans to initiate some of its additional domatinostat trials...

Share
bullish4SC
03 May 2018 13:32Issuer-paid

4SC - Yakult starts Phase II trial; fresh 4SC-202 data

Yakult, 4SC’s development partner for resminostat in Japan, has reached two clinical development milestones. First, just two weeks after it joined...

Share
bullish4SC
28 Mar 2018 13:24Issuer-paid

4SC - Yakult joined the pivotal RESMAIN study

Together with its Q417 results announced last week, 4SC also reported progress with its R&D activities. All three lead assets – resminostat,...

Share
bullish4SC
09 Feb 2018 11:06Issuer-paid

4SC - Steady R&D newsflow

Over the past several months 4SC has reported progress with both its clinical-stage assets – resminostat and 4SC-202. The pivotal trial with...

Share
bullish4SC
30 Oct 2017 10:32Issuer-paid

Becoming a dermato-oncology expert

4SC’s new core strategy revealed earlier this year has focused on dermato-oncological indications, while its assets for other indications are...

Share
No more insights
x